Apolipoprotein B Outperforms LDL Particle Number as a Marker of Cardiovascular Risk in the UK Biobank

Both apolipoprotein B and LDL particle number count atherogenic particles — so which is the better risk marker when they disagree? This large UK Biobank analysis ran the head-to-head test.

Across more than 41,000 primary-prevention participants, the answer was apoB. When apoB was discordantly higher than LDL particle number, cardiovascular risk rose sharply and progressively — at 30 percent discordance, the hazard for coronary disease was 2.5-fold. But when LDL particle number was discordantly higher than apoB, there was no significant excess risk. The excess risk tracked apoB, not LDL-P.

The practical implication favors the cheaper, more standardized test. ApoB — a widely available, inexpensive assay — captured atherogenic risk at least as well as, and in discordance better than, the more elaborate particle-counting NMR measurement. It strengthens the case for apoB as the preferred single measure of atherogenic burden.

We rate the evidence strong. A large, contemporary cohort with a clean discordance design, it adds important recent weight to the argument that apoB should be the atherogenic marker of choice.